Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing dropless platform therapies for glaucoma, corneal disorders, and retinal diseases. Key products include the iStent family of devices, iDose TR (intracameral implant), Photrexa (keratoconus treatment), and the recently FDA-approved Epioxa.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $133,537 | $96,670 | $364,321 | $277,982 |
| Gross Profit | $104,706 | $74,086 | $284,278 | $212,590 |
| Gross Margin | 78% | 77% | 78% | 76% |
| Operating Expenses | $121,071 | $98,746 | $344,010 | $306,290 |
| Loss from Operations | $(16,365) | $(24,660) | $(59,732) | $(93,700) |
| Net Loss | $(16,231) | $(21,409) | $(54,034) | $(112,792) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.39) | $(0.95) | $(2.18) |
Liquidity and Balance Sheet Highlights (as of Sept 30, 2025)
- Cash and Cash Equivalents: $98.2 million
- Short-term Investments: $175.5 million
- Total Current Assets: $454.8 million
- Total Current Liabilities: $87.5 million
- Working Capital: $367.3 million
- Accumulated Deficit: $(799.5) million
- Debt: No convertible senior notes outstanding (redeemed/exchanged in 2024); finance lease liabilities of $68.5 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 38% in Q3 2025 and 31% in the nine months ended Sept 30, 2025, compared to the prior year. This was driven primarily by higher volumes of iDose TR sales, which command a higher net sales price.
- Profitability Improvement: Net loss decreased 24% in Q3 and 52% in the nine-month period year-over-year, reflecting revenue growth outpacing expense increases.
- Acquisitions: In May 2025, the company acquired Mobius Therapeutics for $12.4 million (net of cash) to add Mitosol to its portfolio. In April 2025, it purchased a 40,000 sq. ft. building in Aliso Viejo for $16.6 million.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 30% in Q3 and 23% in the nine-month period, driven by increased compensation (including stock-based compensation), commercial infrastructure growth, and higher reserves for accounts receivable.
- Non-Operating Items: Non-operating income improved significantly in the nine-month period due to the absence of $18.0 million in charges associated with the convertible notes exchange that occurred in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Epioxa Launch: Following FDA approval in October 2025, Glaukos plans to begin commercializing Epioxa (an incision-free keratoconus therapy) in Q1 2026. Management anticipates a transition period where sales may shift from Photrexa to Epioxa.
- iDose TR Reimbursement: Utilization is expected to increase as reimbursement processes become more consistent across Medicare Administrative Contractors (MACs).
- Regulatory Pipeline: A Prescription Drug User Fee Act (PDUFA) date of January 2026 is set for a supplemental NDA regarding the re-administration of iDose TR.
- Capital Expenditures: The company anticipates higher capital expenditures in 2025 and beyond, including a planned $80+ million investment in a new R&D and manufacturing facility in Huntsville, Alabama, with construction expected to begin in 2026.
Risks and Contingencies
- Reimbursement Uncertainty: Finalized Local Coverage Determinations (LCDs) by five MACs restrict the combination of certain MIGS procedures, potentially impacting iStent family sales volumes. Reimbursement rates for iDose TR and Epioxa remain subject to payer determination.
- Government Shutdown: A U.S. government shutdown beginning October 1, 2025, may impact FDA review timelines and reimbursement services, though no material adverse impact has been experienced to date.
- Commercial Success: The business relies heavily on the commercial success of iDose TR and Epioxa. Failure to achieve market adoption or maintain reimbursement could materially impact results.
- Supply Chain: Reliance on limited suppliers for key components and potential disruptions from tariffs or geopolitical events pose risks to manufacturing and gross margins.
Investor Verification Checklist
- Reimbursement Status: Verify the current status of professional fee payment rates for iDose TR across all seven MACs and the impact of LCDs on iStent infinite standalone procedures.
- Epioxa Commercialization: Monitor the timeline and initial uptake of Epioxa following its planned Q1 2026 launch and the transition strategy from Photrexa.
- Accounts Receivable: Review the significant increase in accounts receivable ($98.7M vs $60.7M prior year-end) and the associated allowance for credit losses ($8.1M), driven by extended payment terms for iDose TR.
- Contingent Consideration: Track the $80 million potential milestone payments and royalty obligations associated with the Mobius Therapeutics acquisition.
- Cash Burn Rate: Assess the sustainability of the current cash position ($273.7M in cash/investments) against operating cash outflows and planned capital expenditures for the Huntsville facility.